Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-168 monotherapy versus investigator's choice in relapsed or refractory non-GCB diffuse large B-cell lymphoma
CTR20253693Phase 2Active
- Sponsor
- Lupeng Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10561 in diffuse large B-cell lymphoma (DLBCL), sponsored by Lupeng Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
HS-10561
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20253693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253693.